Bracco Imaging has launched VUEWAY injection (gadopiclenol) in Mexico following approval from COFEPRIS in September 2025. The contrast agent is approved for use in magnetic resonance imaging for adults and children aged 2 years and older. VUEWAY enables effective contrast enhancement whilst reducing gadolinium exposure for patients. This aligns with radiology societies' guidance on using the lowest effective dose when contrast-enhanced imaging is required. The product is now approved in 38 countries worldwide, with more than 4 million patient doses administered. In the EU and US, the approved indication extends to neonates and infants. Gadopiclenol was initially invented by Guerbet with subsequent contribution from Bracco IP. The two companies entered a worldwide collaboration on manufacturing and research and development in December 2021.

Bracco Imaging has received the 2026 EcoVadis Platinum Medal for the second consecutive year, placing it among the top 1% of companies assessed by the sustainability rating platform. The Milan-based diagnostic imaging company improved its overall score from 83 to 91 out of 100, recording gains across all four assessment categories. The recognition reflects strengthened sustainability practices, including expanded ISO certification coverage across production sites and revised procurement processes. Bracco also obtained voluntary limited assurance for selected sustainability indicators. "This result is especially meaningful because it reflects not only continued top-tier performance, but measurable improvement," said Fulvio Renoldi Bracco, vice chairman and chief executive officer. The company generates approximately €2 billion in annual revenues and operates in over 100 countries.

ACIST Medical Systems, a Bracco company, has received US FDA clearance for its ACIST Pro Diagnostic System, a variable-rate contrast management solution for image-guided cardiovascular procedures. The system is now launching in the United States. ACIST Pro evolves the company's CVi technology, which clinical use has shown reduces contrast use by an average of 45ml, cuts contrast-induced acute kidney injury by 30%, and saves approximately five minutes per procedure compared to manual injection. The system delivers automated, real-time precision for contrast media in interventional cardiology. The device was previously launched in Japan in 2025 and received CE mark approval for European markets in February 2026. ACIST Medical Systems is part of the Bracco Group, which invests around 9% of its reference turnover in research and development.